Table 1– Baseline characteristics of the pulmonary hypertension cohort
Subjects n50
Age years54.4±15.1
Female %56
Mean BSA m21.98
WHO PH aetiology
 Group 127 (54)
 Group 27 (14)
 Group 310 (20)
 Group 43 (6)
 Group 53 (6)
PH-specific treatment
 No treatment29 (58)
i.v. prostanoid alone4 (8)
 Sildenafil alone12 (24)
 Other#5 (10)
  • Data are presented as mean±sd or n (%), unless otherwise stated. BSA: body surface area; WHO: World Health Organization; PH: pulmonary hypertension. #: other PH-specific treatments were bosentan alone (n=1), bosentan+sildenafil (n=1), i.v. prostanoid+sildenafil (n=2) and calcium channel blocker (n=1).